

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Oveporexton for treating type 1 narcolepsy [ID6622]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<u>Company</u> • Takeda (oveporexton) <u>Patient/carer groups</u> • Asthma & Lung UK • Blood Pressure UK • Brain and Spine Foundation • Brain Charity • Cardiovascular Care Partnership • Circulation Foundation • Different Strokes • Genetic Alliance UK • HEART UK • Hope2Sleep • Narcolepsy UK • Neurological Alliance • Pulmonary Hypertension Association UK • Pumping Marvellous Foundation • Sleep Apnoea Trust • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • The Sleep Charity <u>Healthcare professional groups</u> • Association for Respiratory Technology and Physiology • Association of British Neurologists • Association of Respiratory Nurses • British & Irish Hypertension Society • British and Irish Association of Stroke Physicians • British Association for Nursing in Cardiovascular Care • British Cardiovascular Society • British Geriatrics Society	<u>General</u> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government <u>Comparator companies</u> • ADVANZ Pharma (fluoxetine, venlafaxine) • AS Kalceks (sodium oxybate) • Aspire Pharma (venlafaxine) • Atnahs Pharma (solriamfetol) • Aurobindo Pharma (fluoxetine, modafinil, venlafaxine) • Bioprojet (pitolisant) • Brown & Burk (dexamfetamine, fluoxetine) • Cipla (fluoxetine) • Dexcel Pharma (venlafaxine) • Dr. Reddy's Laboratories (fluoxetine) • Exeltis (methylphenidate)

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
- British Heart Foundation - British Neuropathological Society - British Sleep Society - British Society for Heart Failure - British Thoracic Society - Interstitial Lung Diseases Interdisciplinary Network - National Heart and Lung Institute - National Neurosciences Advisory Group - OSA Alliance - Primary Care and Community Neurology Society - Primary Care Cardiovascular Society - Royal College of General Practitioners - Royal College of Nursing - Royal College of Pathologists - Royal College of Physicians - Royal Pharmaceutical Society - Royal Society of Medicine - Society for Cardiological Science and Technology - UK Clinical Pharmacy Association <u>Others</u> - Department of Health and Social Care - NHS England	- Flamingo Pharma (fluoxetine) - Flynn Pharma (methylphenidate) - Genus Pharmaceuticals (venlafaxine) - InfectoPharm (methylphenidate) - Janssen-Cilag (methylphenidate) - Krka (venlafaxine) - Laboratorios Liconsa (methylphenidate) - Martindale Pharma (methylphenidate, venlafaxine) - Medice (dexamfetamine, methylphenidate) - Morningside Healthcare (fluoxetine, venlafaxine) - Neuraxpharm (fluoxetine, methylphenidate) - Pinewood Healthcare (fluoxetine) - Reig Jofre (sodium oxybate) - Rosemont Pharmaceuticals (dexamfetamine, fluoxetine, venlafaxine) - Sandoz (methylphenidate) - Sovereign Medical (dexamfetamine, venlafaxine) - Strides Pharma (fluoxetine, methylphenidate) - Sun Pharmaceuticals (venlafaxine) - SyriMed (fluoxetine) - Takeda (lisdexamfetamine, methylphenidate) - Teva Pharma (modafinil) - UCB Pharma (sodium oxybate) - Viartis (clomipramine, methylphenidate, venlafaxine) - Zentiva (methylphenidate) <u>Relevant research groups</u> - Brain Research UK - British Association for Lung Research - British Society for Cardiovascular Research - Cochrane Airways Group - Cochrane Heart, Stroke and Circulation - Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	• European Council for Cardiovascular Research • Genomics England • Heart Research UK • Institute of Neurology and Neurosurgery • MRC Clinical Trials Unit • National Institute for Cardiovascular Outcomes Research • National Institute for Health & Care Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.